[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-330429-105":59,"doc-detail-330429-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","esco2s-oncogenic-role-in-human-tumors-a-pan-cancer-analysis-and-experimental-validation","ESCO2’s oncogenic role in human tumors - a pan-cancer analysis and experimental validation","","Purpose Establishment of sister chromatid cohesion N-acetyltransferase 2 (ESCO2) is involved in mitotic S-phase adhesins acetylation and sister chromatid bridging, yet prior ESCO2 studies were limited to few cancers. This work performs a systematic pan-cancer investigation of ESCO2 in diagnosis, prognosis, and effector function. Methods Public resources including TCGA, GTEx, UALCAN, and TISCH were integrated for differential expression, survival, mutation, single-cell and immune infiltration analyses, followed by in vitro validation in clear cell renal cell carcinoma. Results Across 33 cancer types, 30 showed higher ESCO2 in tumors; survival associations varied by cancer, and ESCO2 correlated with stage and size in several cohorts. Function analysis linked ESCO2 to mitosis, cell cycle, and DNA damage repair, with CDK1 as a downstream gene. ESCO2 knockdown suppressed A498 and T24 proliferation, invasion, and migration. Conclusions ESCO2 emerges as a pan-cancer biomarker and oncogene and supports therapeutic targeting potential.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/esco2s-oncogenic-role-in-human-tumors-a-pan-cancer-analysis-and-experimental-validation/330429/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/esco2s-oncogenic-role-in-human-tumors-a-pan-cancer-analysis-and-experimental-validation/330429.png","ImageObject",300,407,{"name":92,"@type":93},"Ava Thompson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main objective of this pan-cancer study on ESCO2?","Question",{"text":112,"@type":113},"To systematically evaluate ESCO2’s role in cancer diagnosis, prognosis, and effector function, since previous research focused only on a limited number of cancer types.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which datasets and analytical components were used to study ESCO2 across cancers?",{"text":117,"@type":113},"The study integrates TCGA, GTEx, UALCAN, and TISCH, performing differential expression, survival analyses, gene mutation assessment, single-cell analysis, and tumor immune cell infiltration analysis.",{"name":119,"@type":110,"acceptedAnswer":120},"How was ESCO2 validated experimentally, and what were the key effects?",{"text":121,"@type":113},"In vitro experiments confirmed ESCO2 impacts on clear cell renal cell carcinoma cell proliferation and invasion, and ESCO2 knockdown significantly inhibited A498 and T24 cell proliferation, invasion, and migration.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},330429,1790197499,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","Huang et al. BMC Cancer (2024) 24:452 BMC Cancer  \n[https://doi.org/10.1186/s12885-024-12213-w](https://doi.org/10.1186/s12885-024-12213-w)  \nRESEARCH Open Access  \nESCO2’s oncogenic role in human tumors: a pan-cancer analysis and experimental validation  \nYue Huang 1†, Dapeng Chen2†, Yi Bai3, Yamin Zhang3, Zhiwen Zheng 1, Qingfeng Fu 1, BocunYi 1, Yuchen Jiang 1, Zhihong Zhang 1* and Jianqiang Zhu 1*  \nAbstract  \nPurpose Establishment of sister chromatid cohesion N-acetyltransferase 2 (ESCO2) is involved in the mitotic S-phase adhesins acetylation and is responsible for bridging two sister chromatids. However, present ESCO2 cancer research is limited to a few cancers. No systematic pan-cancer analysis has been conducted to investigate its role in diagnosis, prognosis, and effector function.  \nMethods We thoroughly examined the ESCO2 carcinogenesis in pan-cancer by combining public databases such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression Project (GTEx), UALCAN and Tumor Immune Singlecell Hub (TISCH) . The analysis includes differential expression analysis, survival analysis, cellular effector function, gene mutation, single cell analysis, and tumor immune cell infiltration. Furthermore, we confirmed ESCO2’s impacts on clear cell renal cell carcinoma (ccRCC) cells’ proliferative and invasive capacities in vitro.  \nResults In our study, 30 of 33 cancer types exhibited considerably greater levels of ESCO2 expression in tumor tissue using TCGA and GTEx databases, whereas acute myeloid leukemia (LAML) exhibited significantly lower levels. Kaplan-Meier survival analyses in adrenocortical carcinoma (ACC), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), brain lower grade glioma (LGG), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), mesothelioma (MESO), and pancreatic adenocarcinoma (PAAD) demonstrated that tumor patients with high ESCO2 expression have short survival periods. However, in thymoma (THYM), colon adenocarcinoma (COAD) and rectum adenocarcinoma (READ), ESCO2 was a favorable prognostic factor. Moreover, ESCO2 expression positively correlates with tumor stage and tumor size in several cancers, including LIHC, KIRC, KIRP and LUAD. Function analysis revealed that ESCO2 participates in mitosis, cell cycle, DNA damage repair, and other processes. CDK1 was identified as a downstream gene regulated by ESCO2 . Furthermore, ESCO2 might also be implicated in immune cell infiltration. Finally, ESCO2’S knockdown significantly inhibited the A498 and T24 cells’ proliferation, invasion, and migration.  \n†Yue Huang and Dapeng Chen contributed equally to this work.  \n*Correspondence:  \nZhihong Zhang [drzhangzhihong@163.com](drzhangzhihong@163.com)[ ](drzhangzhihong@163.com)Jianqiang Zhu [zjqwfmu@126.com](zjqwfmu@126.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ([http://creativecommons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/))","cbCaiiJNiNLcGLBh","https://ap.wps.com/l/cbCaiiJNiNLcGLBh","pdf",8361102,15,"English","# Abstract\n# Introduction\n# Methods\n## Data sources and pan-cancer analyses\n## Experimental validation\n# Results\n## Expression and survival associations\n## Functional enrichment and CDK1 regulation\n## Immune infiltration and in vitro effects\n# Conclusions","[{\"question\":\"What is the main objective of this pan-cancer study on ESCO2?\",\"answer\":\"To systematically evaluate ESCO2’s role in cancer diagnosis, prognosis, and effector function, since previous research focused only on a limited number of cancer types.\"},{\"question\":\"Which datasets and analytical components were used to study ESCO2 across cancers?\",\"answer\":\"The study integrates TCGA, GTEx, UALCAN, and TISCH, performing differential expression, survival analyses, gene mutation assessment, single-cell analysis, and tumor immune cell infiltration analysis.\"},{\"question\":\"How was ESCO2 validated experimentally, and what were the key effects?\",\"answer\":\"In vitro experiments confirmed ESCO2 impacts on clear cell renal cell carcinoma cell proliferation and invasion, and ESCO2 knockdown significantly inhibited A498 and T24 cell proliferation, invasion, and migration.\"}]","ESCO2’s oncogenic role in human tumors - a pan-cancer analysis and experimental validation | PDF",1789988866,38]